Orleans Capital Management’s GSK GSK Stock Holding History

Orleans Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-8,044	Closed	-$424K	–	79
2017 Q1	$424K	Sell	8,044 -3,471	-30%	-$176K	0.3%	69
2016 Q4	$554K	Sell	11,515 -14,491	-56%	-$716K	0.4%	64
2016 Q3	$1.4M	Buy	26,006 +520	+2%	+$28.5K	0.97%	47
2016 Q2	$1.38M	Sell	25,486 -6,256	-20%	-$330K	0.96%	47
2016 Q1	$1.61M	Buy	31,742 +843	+3%	+$42K	1.21%	37
2015 Q4	$1.56M	Sell	30,899 -8,330	-21%	-$425K	1.2%	37
2015 Q3	$1.89M	Sell	39,229 -121	-0.3%	-$6.3K	1.5%	29
2015 Q2	$2.05M	Buy	39,350 +3,741	+11%	+$211K	1.45%	30
2015 Q1	$2.05M	Buy	35,609 +21,132	+146%	+$1.21M	1.34%	35
2014 Q4	$773K	Sell	14,477 -26,419	-65%	-$1.48M	0.47%	62
2014 Q3	$2.35M	Buy	+40,896	New	+$2.51M	1.16%	41

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Orleans Capital Management's GSK Position: Q2 2017 in Review

Orleans Capital Management sold out of GSK (GSK) in Q2 2017, closing a stake of 8,044 shares — an estimated $424K sold.

Orleans Capital Management first reported a position in GSK in Q3 2014 and held it in 11 quarters. The position peaked at $2.35M in Q3 2014. 780 funds tracked by Wall St. Rank hold GSK as of Q2 2017.

Orleans Capital Management reported no remaining GSK position as of Q2 2017 after selling out during the quarter.
Orleans Capital Management sold 8,044 GSK shares in Q2 2017, an estimated $424K.
Orleans Capital Management first reported a position in GSK in Q3 2014 and held it in 11 quarters.
Orleans Capital Management's GSK position peaked at $2.35M in Q3 2014.
780 funds tracked by Wall St. Rank held GSK as of Q2 2017.

Based on Orleans Capital Management's 13F filing for Q2 2017, filed 15 Aug 2017.